Rociletinib (CO-1686) USA Expanded Access Program
NCT02547675 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2018-09-25
Summary
To provide access to rociletinib for patients with advanced or metastatic EGFR-mutant NSCLC who have been treated previously with EGFR directed therapy and have evidence of a T790M mutation (T790M+).
Conditions
Interventions
- DRUG
-
Rociletinib
Rociletinib will be administered to patients orally
Sponsors & Collaborators
-
Clovis Oncology, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy
NCT02186301 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
NCT02580708 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)
NCT02349633 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation
NCT06761976 ·Status: AVAILABLE
-
Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung Cancer
NCT00897533 ·Status: COMPLETED
-
A Dose-Escalation Study of RO5083945 in Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors.
NCT00721266 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.
NCT00773383 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
NCT01260181 ·Status: COMPLETED ·Phase: PHASE2
-
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
NCT02322281 ·Status: TERMINATED ·Phase: PHASE3
-
A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.
NCT01250119 ·Status: COMPLETED ·Phase: PHASE2
-
Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for Patients Unfit for Chemotherapy
NCT00452075 ·Status: TERMINATED ·Phase: PHASE2
-
An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT00949910 ·Status: COMPLETED ·Phase: PHASE4
-
A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer
NCT02297425 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations
NCT01287754 ·Status: COMPLETED ·Phase: PHASE4
-
Mutations in the Epidermal Growth Factor Receptor(EGFR) Gene in Non-Small Cell Lung Carcinoma (NSCLC) and the Relation to Response of Treatment With Erlotinib
NCT00815971 ·Status: UNKNOWN
-
A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies
NCT02108964 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC
NCT00294762 ·Status: COMPLETED ·Phase: PHASE2
-
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
NCT03333343 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR
NCT01744925 ·Status: UNKNOWN ·Phase: PHASE2
-
Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC
NCT00997334 ·Status: COMPLETED ·Phase: PHASE2
-
E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C
NCT03623750 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Expanded Access of Sotorasib
NCT04667234 ·Status: NO_LONGER_AVAILABLE
-
Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
NCT00567359 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT)
NCT04031898 ·Status: COMPLETED
-
Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation
NCT01683175 ·Status: UNKNOWN ·Phase: PHASE2